Spero Therapeutics Free Cash Flow (FCF) History (SPRO)

Spero Therapeutics reported −$86.0M in free cash flow for fiscal 2020, a decrease of $35.7M from the previous fiscal year, with a free cash flow margin of −33344.57%.

View full Spero Therapeutics company overview

Spero Therapeutics free cash flow by year

Spero Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20202020-12-31−$86.0M−$35.7M—−33344.57%
20192019-12-31−$50.3M−$8.3M—−1061.45%
20182018-12-31−$42.1M−$2.9M—−1060.54%
20172017-12-31−$39.1M−$9.3M—−1977.67%
20162016-12-31−$29.8M−$19.9M—−8892.24%
20152015-12-31−$9.8M———

Spero Therapeutics free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$9.8M to −$86.0M, a net decrease of $76.2M. Spero Therapeutics's latest reported quarter, Q3 2021, generated −$5.0M in free cash flow, an increase of $16.4M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Spero Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about SPRO yet. Start the conversation.

Write the first post